natgillin/translations-raw huggingface dataset:
Exforge 5 mg/80 mg film-coated tablets Exforge 5 mg/160 mg film-coated tablets Exforge 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/80 mg filmom obložene tablete Exforge 5 mg/160 mg filmom obložene tablete Exforge 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Grapefruit and grapefruit juice should not be consumed by people who are taking Exforge. 
Bolesnici koji uzimaju Exforge ne smiju konzumirati grejp ili sok od grejpa.
Exforge 5 mg/160 mg film-coated tablets 
Exforge 5 mg/160 mg filmom obložene tablete
If you think you may be allergic, talk to your doctor before taking Exforge. 
Ako mislite da biste mogli biti alergični, porazgovarajte sa svojim liječnikom prije uzimanja Exforgea. ako imate teške probleme s jetrom ili probleme sa žuči, poput bilijarne ciroze ili kolestaze.
EU/1/06/370/035 280 film-coated tablets (4x70) EU/1/06/370/038 280 film-coated tablets (20x14) 
EU/1/06/370/035 280 filmom obloženih tableta (4x70) EU/1/06/370/038 280 filmom obloženih tableta (20x14)
Exforge 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
EU/1/06/370/036 280 film-coated tablets (4x70) EU/1/06/370/039 280 film-coated tablets (20x14) 
EU/1/06/370/036 280 filmom obloženih tableta (4x70) EU/1/06/370/039 280 filmom obloženih tableta (20x14)
EU/1/06/370/034 280 film-coated tablets (4x70) EU/1/06/370/037 280 film-coated tablets (20x14) 
EU/1/06/370/034 280 filmom obloženih tableta (4x70) EU/1/06/370/037 280 filmom obloženih tableta (20x14)
Exforge 5 mg/80 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/80 mg filmom obložene tablete amlodipin/valsartan
if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body). 
(Također je bolje izbjegavati Exforge u ranoj trudnoći, vidjeti dio Trudnoća). ako imate jako nizak krvni tlak (hipotenzija). ako imate suženje aortnog zaliska (stenoza aorte) ili kardiogeni šok (stanje u kojem Vaše srce ne može opskrbiti tijelo dovoljnom količinom krvi). ako patite od zatajivanja srca nakon srčanog udara.
Exforge 5 mg/160 mg film-coated tablets amlodipine/valsartan 
Exforge 5 mg/160 mg filmom obložene tablete amlodipin/valsartan
EU/1/06/370/001 7 film-coated tablets EU/1/06/370/002 14 film-coated tablets EU/1/06/370/003 28 film-coated tablets EU/1/06/370/004 30 film-coated tablets EU/1/06/370/005 56 film-coated tablets EU/1/06/370/006 90 film-coated tablets EU/1/06/370/007 98 film-coated tablets EU/1/06/370/008 280 film-coated tablets EU/1/06/370/025 56x1 film-coated tablet (unit dose) EU/1/06/370/026 98x1 film-coated tablet (unit dose) EU/1/06/370/027 280x1 film-coated tablet (unit dose) 
EU/1/06/370/001 7 filmom obloženih tableta EU/1/06/370/002 14 filmom obloženih tableta EU/1/06/370/003 28 filmom obloženih tableta EU/1/06/370/004 30 filmom obloženih tableta EU/1/06/370/005 56 filmom obloženih tableta EU/1/06/370/006 90 filmom obloženih tableta EU/1/06/370/007 98 filmom obloženih tableta EU/1/06/370/008 280 filmom obloženih tableta EU/1/06/370/025 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/026 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/027 280x1 filmom obloženih tableta (jedinična doza)
EU/1/06/370/017 7 film-coated tablets EU/1/06/370/018 14 film-coated tablets EU/1/06/370/019 28 film-coated tablets EU/1/06/370/020 30 film-coated tablets EU/1/06/370/021 56 film-coated tablets EU/1/06/370/022 90 film-coated tablets EU/1/06/370/023 98 film-coated tablets EU/1/06/370/024 280 film-coated tablets EU/1/06/370/031 56x1 film-coated tablet (unit dose) EU/1/06/370/032 98x1 film-coated tablet (unit dose) EU/1/06/370/033 280x1 film-coated tablet (unit dose) 
EU/1/06/370/017 7 filmom obloženih tableta EU/1/06/370/018 14 filmom obloženih tableta EU/1/06/370/019 28 filmom obloženih tableta EU/1/06/370/020 30 filmom obloženih tableta EU/1/06/370/021 56 filmom obloženih tableta EU/1/06/370/022 90 filmom obloženih tableta EU/1/06/370/023 98 filmom obloženih tableta EU/1/06/370/024 280 filmom obloženih tableta EU/1/06/370/031 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/032 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/033 280x1 filmom obloženih tableta (jedinična doza)
EU/1/06/370/009 7 film-coated tablets EU/1/06/370/010 14 film-coated tablets EU/1/06/370/011 28 film-coated tablets EU/1/06/370/012 30 film-coated tablets EU/1/06/370/013 56 film-coated tablets EU/1/06/370/014 90 film-coated tablets EU/1/06/370/015 98 film-coated tablets EU/1/06/370/016 280 film-coated tablets EU/1/06/370/028 56x1 film-coated tablet (unit dose) EU/1/06/370/029 98x1 film-coated tablet (unit dose) EU/1/06/370/030 280x1 film-coated tablet (unit dose) 
EU/1/06/370/009 7 filmom obloženih tableta EU/1/06/370/010 14 filmom obloženih tableta EU/1/06/370/011 28 filmom obloženih tableta EU/1/06/370/012 30 filmom obloženih tableta EU/1/06/370/013 56 filmom obloženih tableta EU/1/06/370/014 90 filmom obloženih tableta EU/1/06/370/015 98 filmom obloženih tableta EU/1/06/370/016 280 filmom obloženih tableta EU/1/06/370/028 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/029 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/370/030 280x1 filmom obloženih tableta (jedinična doza)
What Exforge looks like and contents of the pack Exforge 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side. 
Exforge 5 mg/80 mg tablete su okrugle, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „NV“ na drugoj strani.
The full EPAR for Clopidogrel Acino can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Acino nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This summary was last updated in 02-2012. 
Sažetak je posljednji put ažuriran u 01.2016.
This is then followed by the standard 75 mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome). 
Nakon toga slijedi standardna doza od 75 mg jedanput na dan tijekom najmanje četiri tjedna (u slučaju infarkta miokarda s „elevacijom ST-segmenta”) ili do 12 mjeseci (u slučaju nestabilne angine ili „non-Q” infarkta miokarda).
This means that Clopidogrel Acino is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix. 
To znači da je Clopidogrel Acino sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Plavix.
For more information about treatment with Clopidogrel Acino, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Clopidogrel Acino pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
• patients with peripheral arterial disease (problems with blood flow in the arteries); 
• boluju od bolesti perifernih arterija (problemi s protokom krvi u arterijama);
• patients who have recently had a myocardial infarction (heart attack). 
• su nedavno pretrpjeli infarkt miokarda (srčani udar).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Acino. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Clopidogrel Acino.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke. 
To sprečava „lijepljenje” trombocita, čime se smanjuje rizik od formiranja krvnih ugrušaka i pomaže pri sprečavanju infarkta miokarda ili moždanog udara.
The standard dose of Clopidogrel Acino is one 75 mg tablet once a day. 
Acino je jedna tableta od 75 mg jedanput dnevno.
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Acino on 28 July 2009. 
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Clopidogrel Acino vrijedi na prostoru Europske unije od 28. srpnja 2009.
Clopidogrel Acino can be started between seven days and six months after the stroke; 
Terapija lijekom Clopidogrel Acino može se započeti u razdoblju od sedam dana do šest mjeseci nakon udara;
Clopidogrel Acino is a ‘generic medicine'. 
Clopidogrel Acino je „generički lijek”.
• patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). 
• su nedavno pretrpjeli ishemijski moždani udar (moždani udar uzrokovan nedovoljnom opskrbom krvi u nekom dijelu mozga).
This is a summary of the European public assessment report (EPAR) for Clopidogrel Acino. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Clopidogrel Acino.
EPAR summary for the public clopidogrel 
EPAR, sažetak za javnost
Because Clopidogrel Acino is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as those of the reference medicine. 
Budući da je Clopidogrel Acino generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i kod referentnog lijeka.
Clopidogrel Acino can be started between a few days and 35 days after the attack; 
Terapija lijekom Clopidogrel Acino može se započeti u razdoblju od nekoliko dana do 35 dana nakon infarkta;
The CHMP concluded that, in accordance with EU requirements, Clopidogrel Acino has been shown to have comparable quality and to be bioequivalent to Plavix. 
Odbor za lijekove za humanu uporabu (CHMP) zaključio je da je, u skladu sa zahtjevima EU-a, potvrđeno kako Clopidogrel Acino posjeduje usporedivu kvalitetu te je bioekvivalentan lijeku Plavix.
Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. 
Clopidogrel sprečava nakupljanje trombocita tako što inhibira tvar naziva ADP od vezanja na posebni receptor na površini.
In acute coronary syndrome, Clopidogrel Acino is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets. 
U slučaju akutnog koronarnog sindroma, terapija načelno započinje udarnom dozom od četiri tablete od 75 mg.
What are the benefits and risks of Clopidogrel Acino? 
Koje su koristi i rizici lijeka Clopidogrel Acino?
Other information about Clopidogrel Acino 
Ostale informacije o lijeku Clopidogrel Acino
The Committee recommended that Clopidogrel Acino be given marketing authorisation. 
Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Clopidogrel Acino.
Because Clopidogrel Acino is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. 
Budući da je Clopidogrel Acino generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje je li lijek bioekvivalentan referentnom lijeku Plavix.
When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). 
Krv se gruša zbog nakupljanja (povezivanja) posebnih stanica u krvi koje se zovu trombociti.
The active substance in Clopidogrel Acino, clopidogrel, is an inhibitor of platelet aggregation. 
Djelatna tvar lijeka Clopidogrel Acino, Clopidogrel, je inhibitor nakupljanja trombocita.
Why has Clopidogrel Acino been approved? 
Zašto je Clopidogrel Acino odobren?
• patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up). 
• boluju od poremećaja naziva „akutni koronarni sindrom”, pri čemu se treba davati s aspirinom (drugi lijek koji sprječava stvaranje krvnih ugrušaka).
Clopidogrel Acino is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). 
Clopidogrel Acino koristi se za sprječavanje problema uzrokovanih stvaranjem krvnih ugrušaka u odraslih bolesnika koji:
What is Clopidogrel Acino? 
Što je Clopidogrel Acino?
Clopidogrel Acino is a medicine that contains the active substance clopidogrel. 
Acino je lijek koji sadrži djelatnu tvar Clopidogrel.
Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a kako koristi nadmašuju utvrđeni rizik, kao i u slučaju lijeka Plavix.
How is Clopidogrel Acino used? 
Kako se Clopidogrel Acino koristi?
How has Clopidogrel Acino been studied? 
Kako je Clopidogrel Acino ispitivan?
How does Clopidogrel Acino work? 
Kako djeluje Clopidogrel Acino?
Cholib fenofibrate / simvastatin 
Cholib fenofibrat / simvastatin
The recommended dose is one tablet a day to be swallowed whole with a glass of water. 
Preporučena doza je jedna tableta dnevno, koja se treba progutati cijela s čašom vode.
Fenofibrate is a ‘PPARα agonist'. 
Fenofibrat je „agonist PPARα“.
The full EPAR for Cholib can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Cholib može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Cholib on 26 August 2013. 
Europska komisija izdaje odobrenje za stavljanje u promet koje za Cholib vrijedi na prostoru Europske unije od 26. kolovoza 2013.
A risk management plan has been developed to ensure that Cholib is used as safely as possible. 
Razvijen je plan upravljanja rizikom kako bi se osiguralo da se lijek Cholib koristi što je sigurnije moguće.
Other information about Cholib 
Druge informacije o lijeku Cholib
Cholib can only be obtained with a prescription and is available as tablets (145/20 mg and 145/40 mg). 
Cholib se izdaje samo na liječnički recept i dostupan je kao tablete (145/20 mg i 145/40 mg).
What is Cholib and what is it used for? 
Što je Cholib i za što se koristi?
It is not intended to provide practical advice on how to use Cholib. 
Svrha sažetka nije davati praktične savjete o načinu korištenja lijeka Cholib.
The cholesterol drawn out of the blood in this way is the ‘bad' cholesterol. 
Kolesterol izvučen iz krvi na ovaj način jest „loš“ kolesterol.
What measures are being taken to ensure the safe and effective use of Cholib? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cholib?
Why is Cholib approved? 
Zašto je Cholib odobren?
It must also not be used in pregnant or breast-feeding women, in people known to have light-induced reactions to fibrates or ketoprofen, or those who have liver or gallbladder disease, pancreatitis, or moderately or severely reduced kidney function, or who have previously had muscle problems while taking statins or fibrates. 
Također se ne smije upotrebljavati u trudnica ili dojilja, u osoba za koje je poznato da imaju fototoksične reakcije na fibrate ili ketoprofen, ili osobe koje boluju od bolesti jetre ili žučnog mjehura, pankreatitisa, odnosno umjereno ili ozbiljno smanjene funkcije bubrega, ili koje su prethodno imale poteškoća s mišićima prilikom uzimanja statina ili fibrata.
What are the risks associated with Cholib? 
Koji su rizici povezani s lijekom Cholib?
This means that it activates a type of receptor called the ‘peroxisome proliferator-activated receptor alpha' (PPARα), which is involved in breaking down fats from diet, especially triglycerides. 
To znači da aktivira tip receptora naziva „peroksisomski proliferator aktivirajućih receptora alfa" (PPARα), koji je uključen u razgradnju masti iz prehrane, posebice triglicerida.
The second active substance, simvastatin, belongs to the group called ‘statins'. 
Druga djelatna tvar, simvastatin, ubraja se u grupu naziva „statini“.
With regard to the safety of Cholib, the side effects reported in the studies were consistent with what is known about the two active substances and there were no major concerns. 
S obzirom na sigurnost lijeka Cholib, nuspojave prijavljene u ispitivanjima bile su konzistentne s nuspojavama koje su poznate za dvije djelatne tvari, te ne postoje veći razlozi za zabrinutost.
In a main study comparing Cholib 145/20 mg with simvastatin 40 mg in 1,050 patients not adequately treated with 20 mg simvastatin alone, triglyceride levels decreased by around 36% with Cholib after 12 weeks compared with 12% with simvastatin. 
U glavnom ispitivanju u kojem je uspoređen lijek Cholib 145/20 mg sa simvastatinom 40 mg u 1.050 bolesnika koji nisu na primjeren način liječeni samo s 20 mg simvastatina, razine triglicerida smanjile su se za otprilike 36% s lijekom Cholib nakon 12 tjedana u usporedbi s 12% sa simvastatinom.
The active substances in Cholib, fenofibrate and simvastatin, work in different ways and their actions have a complementary effect. 
Djelatne tvari u lijeku Cholib, fenofibrat i simvastatin, djeluju na različite načine, a njihovo djelovanje ima komplementaran učinak.
The Committee also noted that the combination of fenofibrate and simvastatin is already being used in clinical practice. 
Povjerenstvo je također odlučilo da se kombinacija fenofibrata i simvastatina već koristi u dobroj kliničkoj praksi.
The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the combination of fenofibrate and simvastatin has been shown to be effective at improving blood fat levels. 
Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji smatra da se kombinacija fenofibrata i simvastatina pokazala djelotvornom u poboljšavanju razina masti u krvi.
Two further studies compared Cholib with other statins (atorvastatin and pravastatin) and showed Cholib to be more effective than those statins given alone. 
Dva daljnja ispitivanja usporedila su Cholib s drugim statinima (atorvastatinom i pravastatinom) i dokazala da je Cholib djelotvorniji od primjene samo statina.
It showed that Cholib led to a greater reduction in triglyceride levels (33% versus 7%) and to higher levels of good cholesterol (6% increase versus a 1% decrease). 
Pokazalo se da je Cholib rezultirao većim smanjenjem razina triglicerida (33% u odnosu na 7%), te povišenom razinom dobrog kolesterola (6% povećanje u odnosu na 1% smanjenja).
In addition, levels of good cholesterol increased by around 7% with Cholib compared with around 2% with simvastatin. 
Nadalje, razine dobrog kolesterola povećale su se za otprilike 7% s lijekom Cholib u usporedbi s otprilike 2% sa simvastatinom.
Cholib is a medicine for improving blood fat levels. 
Cholib jest lijek za poboljšavanje razina masti u krvi.
Cholib is to be used in adults at high risk of heart disease whose levels of ‘bad' cholesterol (LDL cholesterol) are already being controlled with the corresponding dose of simvastatin alone. 
Cholib je indiciran za uporabu u odraslih osoba koje su izložene riziku od srčanih bolesti čije se razine „lošeg“ kolesterola (LDL kolesterola) već kontroliraju samo odgovarajućom dozom simvastatina.
When these receptors are activated, the breakdown of fats speeds up, which helps clear the blood of ‘bad' cholesterol and triglycerides. 
Nakon što su ovi receptori aktivirani, razgradnja masti se ubrzava, što pomaže pri čišćenju krvi od „lošeg“ kolesterola i triglicerida.
This is a summary of the European public assessment report (EPAR) for Cholib. 
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Cholib.
The Committee therefore concluded that Cholib's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Povjerenstvo je stoga zaključilo da koristi lijeka Cholib nadmašuju s njim povezane rizike te je preporučilo njegovo odobrenje za korištenje u Europskoj uniji.
Another study compared Cholib 145/40 mg with simvastatin 40 mg in 450 patients not adequately treated with 40 mg simvastatin alone. 
Drugo ispitivanje usporedilo je Cholib 145/40 mg sa simvastatinom 40 mg u 450 bolesnika koji nisu na primjeren način liječeni samo sa 40 mg simvastatina.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cholib, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku za lijek Cholib uključene su sigurnosne informacije uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Cholib must not be used in people who are hypersensitive (allergic) to peanuts, soya lecithin or any of the ingredients of the medicine. 
Cholib se ne smije primjenjivati u osoba koje su preosjetljive (alergične) na kikiriki, soja lecitin ili bilo koju drugu pomoćnu tvar.
What benefits of Cholib have been shown in studies? 
Koje koristi lijeka Cholib su dokazane u ispitivanjima?
As the liver needs cholesterol to produce bile, the reduced blood cholesterol level causes the liver cells to produce receptors that draw cholesterol from the blood, reducing its level even further. 
S obzirom da je jetri potreban kolesterol za proizvodnju žući, smanjena razina kolesterola u krvi uzrokuje da stanice jetre proizvode receptore koji privlače kolesterol iz krvi, te još više smanjuju njegovu razinu.
The most common side effects with Cholib are raised blood creatinine levels, upper respiratory tract infection (colds), increased blood platelet counts, gastroenteritis (diarrhoea and vomiting) and increased levels of alanine aminotransferase (a liver enzyme). 
Najčešće nuspojave s lijekom Cholib su povišene razine kreatinina u krvi, upala gornjeg respiratornog trakta (prehlade), povećanje broja trombocita, gastroenteritis (proljev i povraćanje) i povišene razine alanin-aminotransferaze (enzima jetre).
It reduces total blood cholesterol by blocking the action of HMG-CoA reductase, an enzyme in the liver involved in the production of cholesterol. 
Smanjuje ukupan kolesterol u krvi tako što inhibira djelovanje HMG-CoA reduktaze, enzima u jetri uključenog u proizvodnju kolesterola.
In all studies the reductions in triglycerides and the increases in good cholesterol were higher with Cholib than with a statin alone. 
U svim je ispitivanjima smanjenje triglicerida i povećanje dobrog kolesterola bilo veće s lijekom Cholib nego samo sa statinom.
For practical information about using Cholib, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o korištenju lijeka Cholib bolesnici trebaju pročitati u uputi o lijeku ili se obratiti svom liječniku ili ljekarniku.
Grapefruit juice should be avoided during Cholib treatment as this is known to alter the amount of simvastatin in the blood. 
Tijekom liječenja lijekom Cholib treba izbjegavati sok od grejpa s obzirom da je poznato da mijenja količinu simvastatina u krvi.
For more information about treatment with Cholib, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Cholib pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Cholib has been shown to be more effective than statins alone in reducing levels of triglycerides and increasing levels of good cholesterol. 
Cholib se pokazao djelotvornijim od samog statina u smanjivanju razina triglicerida i u povećavanju razina dobrog kolesterola.
It contains two active substances, fenofibrate and simvastatin, and is used together with a low fat diet and exercise with the aim of reducing patients' levels of triglycerides (a type of fat) and increasing their levels of ‘good' cholesterol (HDL cholesterol). 
Sadrži dvije djelatne tvari, fenofibrat i simvastatin te se primjenjuje se zajedno s dijetom siromašnom mastima i tjelovježbom sa ciljem smanjivanja razina triglicerida (tipa masti) u bolesnika i povećavanja razina „dobrog“ kolesterola (HDL kolesterol).